People news from the 02/27/07 news brief

MANUFACTURERS Wyeth has announced the promotion of Joseph Mahady president - global business, Wyeth Pharmaceuticals and SVP, Wyeth. Mahady will continue to report to Bernard Poussot, president, CEO and vice chairman of Wyeth. In his new role, Mahady assumes operational responsibility for Wyeth's global pharmaceutical business, including Europe/Middle East/Africa, Asia/Pacific, and Wyeth Nutrition, in addition to his current responsibilities for the Americas and the four strategic global business units – pharmaceuticals, biopharma, vaccines and women's healthcare. Mahady joined Wyeth in 1979 as a pharmacist in regulatory affairs. Following his progression through several commercial positions, he was appointed president, U.S. in 1995. He has since assumed responsibilities for the remainder of the Americas and for the global business units. MedImmune has added Jamie Harrell as VP, infectious disease marketing, and Mark Stanton, VP, managed markets. Harrell is responsible for leading the strategic direction of marketing activities for Synagis (palivizumab) as well as the commercialization of MedImmune's next-generation monoclonal antibody. Prior to joining MedImmune, Harrell was senior director, marketing and global market development at Centocor, In this role, he was responsible for supporting the growth of Centocor's anti-TNF monoclonal antibody in ex-U.S. markets in conjunction with Schering-Plough. Harrell joined Centocor in 1999 and held positions of increasing responsibility, including senior director, marketing, rheumatology franchise, and associate director, marketing, for Centocor's cardiovascular business unit. Prior to Centocor, he held positions at Searle Pharmaceuticals and Rhone-Poulenc Rorer. As MedImmune's new VP, managed markets, Stanton will leverage his 12 years of managed care experience to build and lead MedImmune's integrated strategy to support all products in the managed care market. In his previous position at Endo Pharmaceuticals, he was the director, corporate accounts, responsible for the development of national managed market activities, including managed care organizations, pharmacy benefit management and group purchasing organizations. Prior to joining Endo, Stanton held positions of increasing responsibility at Serono, leading to director, managed care and contracting. Earlier in his career, Stanton held sales and marketing positions at the Rhone-Poulenc Group and the Boehringer Mannheim Corporation. AGENCIES Axis Healthcare Communications has announced the following appointments. Bianca Ruzicka has been named managing director at medical communications agency Helix San Francisco. Dee Partridge has been appointed VP strategic development for medical communications agency ApotheCom. David Dunn has been appointed managing director of ApotheCom’s Yardley, PA office. MEDIA The journal Stem Cells has named two new associate editors – Donald Phinney of Tulane University, and Miodrag Stojkovic of Centro de Investigacion Principe Felipe in Spain.
You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.